Κυριακή 21 Ιουλίου 2019

Journey’s end: the quest for BRCA-like hereditary breast cancer genes is nearly over 
 
W D FoulkesP Polak
 
 
Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark? 
 
S L GaillardR L Coleman
 
 
Hyperprogression during immunotherapy: do we really want to know? 
 
S ChampiatB BesseA Marabelle
 
 
Circulating tumor cells are prognostic in SCLC, but still lack clinical application 
 
M TammingaH J M Groen
 
 
Early-phase clinical drug development of novel agents: a changing paradigm 
 
M de MiguelE Calvo
 
 
Rare cancers: from centralized referral to networking 
 
P G Casali
 
 
Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop 
 
P LoriganA M M Eggermont
 
 
Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis 
 
M RotaM PizzatoC La VecchiaP Boffetta
 
 
 
Reviews
 
 
 
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? 
 
A MatikasT FoukakisS SwainJ Bergh
 
 
Targeting the PI3-kinase pathway in triple-negative breast cancer 
 
J PascualN C Turner
 
 
Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications border= 
 
J Witte ; K MehlisB SurmannR LingnauO Damm ...
 
 
 
Original articles
 
 
 
 
Breast tumors
 
 
 
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers border= 
 
K NonesJ JohnsonF NewellA M PatchH Thorne ...
 
 
 
Gynecological tumors
 
 
 
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study 
 
U A MatulonisR Shapira-FrommerA D Santin ; A S LisyanskayaS Pignata ...
 
 
 
Gastrointestinal tumors
 
 
Editor's Choice
 
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy 
 
J HamfjordT K Guren ; O DajaniJ S JohansenB Glimelius ...
 
 
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer 
 
A B SchrockC OuyangJ SandhuE Sokol ; D Jin ...
 
 
 
Thoracic tumors
 
 
 
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer 
 
C G KimK H KimK -H PyoC -F Xin ; M H Hong ...
 
 
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial border= 
 
R Y Tay ; F Fernández-GutiérrezV FoyK BurnsJ Pierce ...
 
Editor's Choice
 
Crizotinib in ROS1 -rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 border= 
 
A T Shaw ; G J RielyY -J BangD -W KimD R Camidge ...
 
 
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer 
 
R J KellyF A ShepherdA KrivoshikF Jie ; L Horn
 
 
 
Early drug development
 
 
 
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors 
 
M D HellmannT -W KimC B LeeB -C Goh ; W H Miller, Jr. ...
 
 
 
Sarcoma
 
 
Editor's Choice
 
Surgery in reference centers improves survival of sarcoma patients: a nationwide study border= 
 
J -Y BlayC Honoré ; E StoeckleP MeeusM Jafari ...
 
 
 
Melanoma
 
 
Editor's Choice
 
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma 
 
Y J L JansenE A Rozeman ; R MasonS M GoldingerM H Geukes Foppen ...
 
 
 
Cancer prevention
 
 
Editor's Choice
 
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy border= 
 
U Pastorino ; M SilvaS SestiniF SabiaM Boeri ...
 
 
 
Letters to the editor
 
 
 
Interactions between direct anticoagulants and chemotherapy 
 
M SorigueE SarrateM D Miljkovic
 
 
RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor 
 
F JouenneC Reger de MouraG LorillonV Meignin ; N Dumaz ...
 
 
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection 
 
J RosI MatosJ Martin-Liberal
 
 
 
Corrigenda
 
 
 
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors 
 
C SerranoJ CortésL De Mattos-ArrudaM BelletP Gómez ...
 
 
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis 
 
J CortesV CalvoN Ramírez-MerinoJ O'Shaughnessy ; A Brufsky ...
 
 
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 
 
S LoiblI MajewskiV Guarneri ; V NekljudovaE Holmes ...
 
 
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 
 
G CuriglianoH J BursteinE P. WinerM GnantP Dubsky ...

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου